Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 94

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 94
---
 six -monthperiod ended June30, 2024. The following unaudited pro forma condensed combined statements of operations for the year ended June 30, 2024, combine: •the historical audited combined statement of operations of OmnigenicsAI for the year ended June30, 2024; and •the historical statement of operations of APx for the twelve -monthperiod ended June30, 2024, using its unaudited consolidated statements of operations for the six -monthperiod ended June30, 2024, added with its audited consolidated statements of operations for the fiscal year ended December31, 2023, deducting its unaudited consolidated statements of operations for the six -monthperiod ended June30, 2023. The unaudited pro forma combined statement of operations was prepared giving pro forma effect to the Business Combination as if it had occurred on July 1, 2023, the beginning of the earliest period presented. For more information about the Business Combination see the section titled “ The Business Combination.” The unaudited pro forma condensed combined financial information has been prepared assuming: • Scenario 1 — Assuming no redemptions for cash: This presentation assumes that no SPAC Shareholders exercise redemption rights with respect to their SPAC Ordinary Shares upon consummation of the Business Combination; and considers that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” • Scenario 2 — Assuming redemptions of 50% of the outstanding Public Shares for cash: This presentation assumes that holders of Public Shares exercise their redemption rights with respect to 50% of Public Shares upon consummation of the Business Combination at a redemption price of approximately $12.05 per share as of December31, 2024 (fair value as of said date). Scenario 2 includes all adjustments contained in Scenario 1 and presents additional adjustments to reflect the effect of the redemptions of 50% of the Public Shares; and assumes that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” and • Scenario 3 — Assuming redemptions of 100% of outstanding Public Shares for cash: This presentation assumes that holders of